• +1-646-491-9876
    • +91-20-67278686

    Search

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2016

    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2016

    • Report Code ID: RW0001506645
    • Category Pharmaceuticals
    • No. of Pages 102
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's, 'BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted pipeline therapeutics.

    The report provides comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Report Scope

    - The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
    - The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) Overview 8
    Therapeutics Development 9
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Stage of Development 9
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Therapy Area 10
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Indication 11
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Products Glance 14
    Late Stage Products 14
    Early Stage Products 15
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Companies 16
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Products under Development by Universities/Institutes 22
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Assessment 24
    Assessment by Monotherapy/Combination Products 24
    Assessment by Mechanism of Action 25
    Assessment by Route of Administration 27
    Assessment by Molecule Type 28
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 30
    Addex Therapeutics Ltd 30
    Array BioPharma Inc. 31
    AstraZeneca Plc 32
    Chronos Therapeutics Limited 33
    Daiichi Sankyo Company, Limited 34
    Exelixis, Inc. 35
    Ignyta, Inc. 37
    Loxo Oncology, Inc. 38
    PharmatrophiX, Inc. 39
    SOM Biotech SL 40
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Drug Profiles 41
    AR-523 - Drug Profile 41
    Product Description 41
    Mechanism Of Action 41
    R&D Progress 41
    AZ-64 - Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    AZD-7451 - Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    BNN-27 - Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    cabozantinib s-malate - Drug Profile 45
    Product Description 45
    Mechanism Of Action 45
    R&D Progress 45
    CTDP-003 - Drug Profile 62
    Product Description 62
    Mechanism Of Action 62
    R&D Progress 62
    DS-6051 - Drug Profile 63
    Product Description 63
    Mechanism Of Action 63
    R&D Progress 63
    entrectinib - Drug Profile 64
    Product Description 64
    Mechanism Of Action 64
    R&D Progress 64
    lestaurtinib - Drug Profile 70
    Product Description 70
    Mechanism Of Action 70
    R&D Progress 70
    LM-22A4 - Drug Profile 71
    Product Description 71
    Mechanism Of Action 71
    R&D Progress 71
    LM-22B10 - Drug Profile 73
    Product Description 73
    Mechanism Of Action 73
    R&D Progress 73
    LOXO-101 - Drug Profile 74
    Product Description 74
    Mechanism Of Action 74
    R&D Progress 74
    PLX-7486 - Drug Profile 78
    Product Description 78
    Mechanism Of Action 78
    R&D Progress 78
    Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 79
    Product Description 79
    Mechanism Of Action 79
    R&D Progress 79
    Small Molecules to Agonize TRKB for Alzheimer's Disease - Drug Profile 80
    Product Description 80
    Mechanism Of Action 80
    R&D Progress 80
    Synthetic Peptide for Neurology - Drug Profile 81
    Product Description 81
    Mechanism Of Action 81
    R&D Progress 81
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Dormant Projects 82
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Discontinued Products 83
    BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Featured News & Press Releases 84
    Oct 10, 2016: Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016 84
    Oct 07, 2016: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors 85
    Oct 03, 2016: CABOMETYX (cabozantinib) Tablets Approved for Advanced Renal Cell Carcinoma, Available at Biologics 86
    Sep 27, 2016: Ipsen Announces Data Presentations of Cabozantinib (Cabometyx) at the European Society for Medical Oncology (ESMO) 2016 Congress 87
    Sep 20, 2016: Exelixis Provides Update on Timing of Key Cabozantinib Clinical Data Presentation at the ESMO 2016 Congress 89
    Sep 19, 2016: EORTC and Ignyta Expand Collaborative Agreement for Precision Medicine 89
    Sep 14, 2016: European Commission Approves Ipsens Cabometyx (Cabozantinib) Tablets For The Treatment Of Advanced Renal Cell Carcinoma In Adults Following Prior Vascular Endothelial Growth Factor (Vegf)-Targeted Therapy 90
    Sep 06, 2016: Exelixis Announces Outcome from First Planned Interim Analysis of the Phase 3 CELESTIAL Trial of Cabozantinib in Patients with Advanced Hepatocellular Carcinoma 91
    Aug 31, 2016: Exelixis presents cabozantinib data at the ESMO 2016 Congress 92
    Aug 31, 2016: Ignyta Announces Approval of an Investigational Device Exemption (IDE) for the Companion Diagnostic Assay to the STARTRK-2 Trial 94
    Jul 22, 2016: Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy 95
    Jul 13, 2016: Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 97
    Jun 15, 2016: Loxo Oncology Accepts Invitation to Present LOXO-101 to the FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee 97
    Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO 98
    May 23, 2016: Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma 100
    Appendix 101
    Methodology 101
    Coverage 101
    Secondary Research 101
    Primary Research 101
    Expert Panel Validation 101
    Contact Us 101
    Disclaimer 102

    List of Tables

    Number of Products under Development for, H2 2016 9
    Number of Products under Development by Therapy Area, H2 2016 10
    Number of Products under Development by Indication, H2 2016 11
    Comparative Analysis by Late Stage Development, H2 2016 14
    Comparative Analysis by Early Stage Products, H2 2016 15
    Number of Products under Development by Companies, H2 2016 16
    Products under Development by Companies, H2 2016 17
    Products under Development by Companies, H2 2016 (Contd..1) 18
    Products under Development by Companies, H2 2016 (Contd..2) 19
    Products under Development by Companies, H2 2016 (Contd..3) 20
    Products under Development by Companies, H2 2016 (Contd..4) 21
    Number of Products under Investigation by Universities/Institutes, H2 2016 22
    Products under Investigation by Universities/Institutes, H2 2016 23
    Assessment by Monotherapy/Combination Products, H2 2016 24
    Number of Products by Stage and Mechanism of Action, H2 2016 26
    Number of Products by Stage and Route of Administration, H2 2016 27
    Number of Products by Stage and Molecule Type, H2 2016 29
    Pipeline by Addex Therapeutics Ltd, H2 2016 30
    Pipeline by Array BioPharma Inc., H2 2016 31
    Pipeline by AstraZeneca Plc, H2 2016 32
    Pipeline by Chronos Therapeutics Limited, H2 2016 33
    Pipeline by Daiichi Sankyo Company, Limited, H2 2016 34
    Pipeline by Exelixis, Inc., H2 2016 35
    Pipeline by Ignyta, Inc., H2 2016 37
    Pipeline by Loxo Oncology, Inc., H2 2016 38
    Pipeline by PharmatrophiX, Inc., H2 2016 39
    Pipeline by SOM Biotech SL, H2 2016 40
    Dormant Projects, H2 2016 82
    Discontinued Products, H2 2016 83

    List of Figures

    Number of Products under Development for, H2 2016 9
    Number of Products under Development by Therapy Area, H2 2016 10
    Number of Products under Development by Top 10 Indication, H2 2016 11
    Comparative Analysis by Late Stage Development, H2 2016 14
    Comparative Analysis by Early Stage Products, H2 2016 15
    Assessment by Monotherapy/Combination Products, H2 2016 24
    Number of Products by Mechanism of Actions, H2 2016 25
    Number of Products by Stage and Mechanism of Actions, H2 2016 25
    Number of Products by Stage and Routes of Administration, H2 2016 27
    Number of Products by Molecule Types, H2 2016 28
    Number of Products by Stage and Molecule Type, H2 2016 28
    Addex Therapeutics Ltd
    Array BioPharma Inc.
    AstraZeneca Plc
    Chronos Therapeutics Limited
    Daiichi Sankyo Company, Limited
    Exelixis, Inc.
    Ignyta, Inc.
    Loxo Oncology, Inc.
    PharmatrophiX, Inc.
    SOM Biotech SL

    Request for Sample

    Report Url https://www.reportsweb.com//bdnf-nt-3-growth-factors-receptor-gp145-trkb-or-neurotrophic-tyrosine-kinase-receptor-type-2-or-trkb-tyrosine-kinase-or-tropomyosin-related-kinase-b-or-ntrk2-or-ec-2-7-10-1-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//bdnf-nt-3-growth-factors-receptor-gp145-trkb-or-neurotrophic-tyrosine-kinase-receptor-type-2-or-trkb-tyrosine-kinase-or-tropomyosin-related-kinase-b-or-ntrk2-or-ec-2-7-10-1-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//bdnf-nt-3-growth-factors-receptor-gp145-trkb-or-neurotrophic-tyrosine-kinase-receptor-type-2-or-trkb-tyrosine-kinase-or-tropomyosin-related-kinase-b-or-ntrk2-or-ec-2-7-10-1-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments